These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
685 related articles for article (PubMed ID: 17596875)
21. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341 [TBL] [Abstract][Full Text] [Related]
22. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Marotta F; Vangieri B; Cecere A; Gattoni A Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567 [TBL] [Abstract][Full Text] [Related]
23. 8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Chuma M; Hige S; Nakanishi M; Ogawa K; Natsuizaka M; Yamamoto Y; Asaka M J Gastroenterol Hepatol; 2008 Sep; 23(9):1431-6. PubMed ID: 18854000 [TBL] [Abstract][Full Text] [Related]
24. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling. Liu R; Tang C; Shen A; Luo H; Wei X; Zheng D; Sun C; Li Z; Zhu D; Li T; Wu Z Oncotarget; 2016 Dec; 7(51):85079-85096. PubMed ID: 27835881 [TBL] [Abstract][Full Text] [Related]
25. Compound Astragalus and Salvia miltiorrhiza extracts suppress hepatocarcinogenesis by modulating transforming growth factor-β/Smad signaling. Hu X; Rui W; Wu C; He S; Jiang J; Zhang X; Yang Y J Gastroenterol Hepatol; 2014 Jun; 29(6):1284-91. PubMed ID: 24329763 [TBL] [Abstract][Full Text] [Related]
26. Transforming growth factor-beta during carcinogenesis: the shift from epithelial to mesenchymal signaling. Matsuzaki K; Okazaki K J Gastroenterol; 2006 Apr; 41(4):295-303. PubMed ID: 16741607 [TBL] [Abstract][Full Text] [Related]
28. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Shindo M; Ken A; Okuno T Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234 [TBL] [Abstract][Full Text] [Related]
29. Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. Yamagata H; Matsuzaki K; Mori S; Yoshida K; Tahashi Y; Furukawa F; Sekimoto G; Watanabe T; Uemura Y; Sakaida N; Yoshioka K; Kamiyama Y; Seki T; Okazaki K Cancer Res; 2005 Jan; 65(1):157-65. PubMed ID: 15665291 [TBL] [Abstract][Full Text] [Related]
30. Hepatitis C viral proteins interact with Smad3 and differentially regulate TGF-beta/Smad3-mediated transcriptional activation. Cheng PL; Chang MH; Chao CH; Lee YH Oncogene; 2004 Oct; 23(47):7821-38. PubMed ID: 15334054 [TBL] [Abstract][Full Text] [Related]
31. Influence of transforming growth factor-β1 and tumor necrosis factor-α genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Radwan MI; Pasha HF; Mohamed RH; Hussien HI; El-Khshab MN Cytokine; 2012 Oct; 60(1):271-6. PubMed ID: 22682513 [TBL] [Abstract][Full Text] [Related]
32. Hepatitis C virus and hepatocellular carcinoma. Colombo M Semin Liver Dis; 1999; 19(3):263-9. PubMed ID: 10518306 [TBL] [Abstract][Full Text] [Related]
33. Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Matsuzaki K Cell Tissue Res; 2012 Jan; 347(1):225-43. PubMed ID: 21626291 [TBL] [Abstract][Full Text] [Related]
34. Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells. Li Q; Liu G; Shao D; Wang J; Yuan H; Chen T; Zhai R; Ni W; Tai G Int J Biochem Cell Biol; 2015 Feb; 59():116-25. PubMed ID: 25526895 [TBL] [Abstract][Full Text] [Related]
35. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways. Zhang C; Li L; Hou S; Shi Z; Xu W; Wang Q; He Y; Gong Y; Fang Z; Yang Y J Ethnopharmacol; 2021 Oct; 279():114350. PubMed ID: 34157326 [TBL] [Abstract][Full Text] [Related]
36. Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocellular carcinoma progression via miR-145/miR-21 mediated Smad3 phosphorylation. Wu C; Chen W; Fang M; Boye A; Tao X; Xu Y; Hou S; Yang Y J Ethnopharmacol; 2019 Mar; 231():98-112. PubMed ID: 30412748 [TBL] [Abstract][Full Text] [Related]
37. Aberrant Smad3 phosphoisoforms in cyst-lining epithelial cells in the Hama T; Nakanishi K; Sato M; Mukaiyama H; Togawa H; Shima Y; Miyajima M; Nozu K; Nagao S; Takahashi H; Sako M; Iijima K; Yoshikawa N; Suzuki H Am J Physiol Renal Physiol; 2017 Dec; 313(6):F1223-F1231. PubMed ID: 28877884 [TBL] [Abstract][Full Text] [Related]
38. Modulation of TGF-beta signaling during progression of chronic liver diseases. Matsuzaki K Front Biosci (Landmark Ed); 2009 Jan; 14(8):2923-34. PubMed ID: 19273245 [TBL] [Abstract][Full Text] [Related]
39. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Pekow JR; Bhan AK; Zheng H; Chung RT Cancer; 2007 Jun; 109(12):2490-6. PubMed ID: 17487861 [TBL] [Abstract][Full Text] [Related]
40. Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway. Pavio N; Battaglia S; Boucreux D; Arnulf B; Sobesky R; Hermine O; Brechot C Oncogene; 2005 Sep; 24(40):6119-32. PubMed ID: 16007207 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]